According to Microchip Biotech's announcement, the company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical recently received the “Notice of Acceptance” issued by the Drug Review Center of the State Drug Administration, and the application for clinical trials of self-developed siglitazide and metformin sustained-release tablets to treat adult patients with type 2 diabetes was accepted. The acceptance date is January 5, 2026. This drug is a fixed-dose combination sustained-release formulation of siglitat sodium and metformin. There are no similar compound preparations in the world that have entered clinical trials. If no negative or questionable opinions are received within 60 days from the date of acceptance, the company can conduct clinical trials, and there is uncertainty about whether it can be carried out.

According to Microchip Biotech's announcement, the company and its wholly-owned subsidiary Chengdu Microchip Pharmaceutical recently received the “Notice of Acceptance” issued by the Drug Review Center of the State Drug Administration, and the application for clinical trials of self-developed siglitazide and metformin sustained-release tablets to treat adult patients with type 2 diabetes was accepted. The acceptance date is January 5, 2026. This drug is a fixed-dose combination sustained-release formulation of siglitat sodium and metformin. There are no similar compound preparations in the world that have entered clinical trials. If no negative or questionable opinions are received within 60 days from the date of acceptance, the company can conduct clinical trials, and there is uncertainty about whether it can be carried out.